Refine
Has Fulltext
- yes (10)
Is part of the Bibliography
- yes (10)
Document Type
- Journal article (10)
Language
- English (10)
Keywords
- carcinomas (2)
- BIRC7 (1)
- CTNNB1 (1)
- CYP2W1 (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- EMT (1)
- FGF-pathway (1)
- FGFR (1)
- IDH1/2 (1)
- NR3C1 (1)
- RNA Expression (1)
- RNAScope (1)
- SOAT1 (1)
- USP8 (1)
- adenomas (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical cancer (1)
- adrenocortical carcinoma (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- astrocytoma (1)
- bioinformatic clustering (1)
- biomarker prediction (1)
- cancer (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- caspase-3 (1)
- catenin (1)
- chromosomes (1)
- comparative genomic hybridization (1)
- drug therapy (1)
- epithelial markers (1)
- expression (1)
- genetic loci (1)
- glioblastoma (1)
- glucocorticoid excess (1)
- high-resolution analysis (1)
- hormones (1)
- hypercortisolism (1)
- immune response (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- in silico analysis (1)
- kinase (1)
- kinases (1)
- lipid droplets (1)
- livin (1)
- machine learning (1)
- malignant tumors (1)
- mesenchymal markers (1)
- mitotane (1)
- neutral loss (1)
- normal adrenal glands (1)
- notch signaling (1)
- patient survival (1)
- recurrence-free survival (1)
- serum (1)
- surgical oncology (1)
- targeted therapy (1)
- tumors (1)
- unsupervised clustering (1)
Institute
- Pathologisches Institut (10) (remove)
Targeting molecular alterations as an effective treatment for isocitrate dehydrogenase-wildtype glioblastoma (GBM) patients has not yet been established. Sterol-O-Acyl Transferase 1 (SOAT1), a key enzyme in the conversion of endoplasmic reticulum cholesterol to esters for storage in lipid droplets (LD), serves as a target for the orphan drug mitotane to treat adrenocortical carcinoma. Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in these tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP, Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as Oil Red O staining. To a small extent SOAT1 was expressed by tumor cells in both tumor entities. In contrast, strong expression was observed in glioma-associated macrophages. Triple immunofluorescence labeling revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively. Furthermore, a notable difference in the amount of LD between GBM and HGA was observed. Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and invasiveness. In addition, the high expression in cells related to neuroinflammation could be beneficial for a concomitant suppression of protumoral microglia/macrophages.